Increased expression of miR-181d is associated with poor prognosis and tumor progression of gastric cancer

Abstract

Aberrant expression of miR-181d has been noted in multiple human cancers, but its role in gastric cancer (GC) remains unclear. The aim of this study was to investigate the expression, clinical significance and functional role of miR-181d in GC. We applied quantitative real-time polymerase chain reaction (qRT-PCR) to quantify the expression of miR-181d in 131 GC tissues, as well as in GC cell lines. The correlation of miR-181d expression with overall survival of GC patients was analyzed using the Kaplan-Meier survival method. Cox regression analysis was conducted to further determine the prognostic value of miR-181d in GC. Cellular functional experiments were carried out to calculate the effect that miR-181d had on GC behaviors. MiR-181d expression was significantly up-regulated in both GC tissues and cells (all $P<$ 0.001), and correlated with TNM stage and lymph node metastasis (all $P<$ 0.05). GC patients in the high miR-181d expression group had shorter survival time than those in the low miR-181d expression group (log-rank $P<$ 0.001). Multivariate Cox regression analysis demonstrated that miR-181d expression and TNM stage were two independent prognostic markers for GC. Overexpression of miR-181d significantly promoted the NCI-N87 and MGC-803 cells proliferation, migration and invasion (all $P<$ 0.05). MiR-181d serves a role as an oncogene in GC by promoting tumor progression. And miR-181d might be a novel predictive marker for the prognosis of GC patients.

Keywords

MicroRNA-181d prognosis progression gastric cancer

1. Introduction

Gastric cancer (GC) is one of the most common type of digestive tract cancers, with high mortality worldwide [1]. Various risk factor have been reported to be associated with GC occurrence, including unhealthy eating habits, smoking, alcohol, as well as virus and bacteria [2]. Up to now, comprehensive treatment in combination with surgery, chemotherapy and radiotherapy remains the most common, as well as effective therapy for GC patients [3]. With the improvements of GC treatment and diagnosis, the overall survival and prognosis remains not so optimistic [4]. The traditional drug therapy for tumors generally means chemotherapy, which always leads to great toxicity to patients and attracts board attention [5]. Recent years, strategies for molecular research becomes a research hotspot, because it has limited and less side effects on normal cells of patients [6]. Thus, it has great significance to explore novel and effective therapeutic targets for GC.

It is well known that microRNAs (miRNAs) are small non-coding RNAs, and serve the function of regulating gene expression at the post-transcription level by binding to the target mRNAs [7, 8]. Previous researches have reported that miRNAs are expressed differentially in various types of cancers [9]. Furthermore, it is also demonstrated that miRNA take participant in various cell procedures such as cell growth, cell cycle, as well as cell development [10]. Recently, the role of miRNAs in GC initiation, development, even progression has aroused more and more attention among scholars. Assumpção et al. conducted a high-throughput sequencing of miRnome of four GC samples, and a number of aberrantly expressed miRNAs have been identified in GC tumor tissues, such as miR-3131, miR-664, miR-150 and so on [11]. Additionally, several miRNAs have been reported to be involved in the tumor progression of GC. For example, Tian et al found that miR-505 was low expressed in GC cells and involved in the development of GC, and HMGB1 was predicted to be a direct target of miR-505 [12]. Guo et al. showed that miR-371-3p was up-regulated in GC tissues which was correlated with aggravation of the GC patients. Besides, the functional assays further proved that miR-371-3p promoted the GC cell proliferation, migration and invasion, suggesting its tumor suppressor role in GC [13]. Notably, miR-181d has been reported to be upregulated in GC tissues compared to normal gastric mucosa [14], but the prognostic value and role of miR-181d in GC remains unknown.

In the present study, the expression patterns and role of miR-181d was validated in GC tissues as well as GC cell lines. Additionally, the clinical and prognostic value of miR-181d in GC were also analyzed.

2. Materials and methods

2.1 Patients and sample collection

Fresh GC tissues and corresponding adjacent normal tissues were obtained form Shengli Oilfield Central Hospital. The adjacent normal tissues were at a distance of more than 5 cm from tumor margin were collected, with the size of about 1.0 cm ${}^{3}$ . All tissues were provided by 131 patients who were diagnosed with GC and underwent gastrectomy from August 2007 to July 2011. The GC diagnosis was based on the World Health Organization criteria and confirmed by two pathologists independently. The enrolled patients did not receive radiotherapy or chemotherapy before the surgery. The tissue samples were snapfrozen in liquid nitrogen immediately following surgery and stored at $-$ 80 ${}^{\circ}$ C. The clinical and pathological information was collected and recorded in Table 1. After surgery, all patients were followed-up by means of a 5-year follow-up survey, and the survival information was obtained by telephone. All procedures of the present study were reviewed and approved by the Ethics Committee of Shengli Oilfield Central Hospital (ID Number: 2006017). Written informed consents were obtained from each participant or their guardians.

2.2 Cell culture and transfection

Human GC cell lines (NCI-N87, AGS, and MGC-803) and the normal gastric mucosa cell GES-1 were acquired from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cell lines were routinely grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and incubated at 37 ${}^{\circ}$ C in a humidified incubator with 5% CO ${}_{2}$ .

The miR-181d mimic, miR-181d inhibitor and the corresponding negative controls of mimic and inhibitor (mimic NC and inhibitor NC) were synthesized and purified by Gene-Pharma (Shanghai, China). Then the GC cell lines were seeded into 6-well plates, and divided into four groups, including miR-181d mimic NC group (mimic NC group), miR-181d mimic group, miR-181d inhibitor NC group (inhibitor NC group), and miR-181d inhibitor group, which were following transfected with miR-181d mimic NC, miR-181d mimic, miR-181d inhibitor NC or miR-181d inhibitor respectively by using Lipofectamine 3000 reagent (Invitrogen, USA) following the manufacturer’s protocols. A total of 48 h after transfection, samples were collected for further experiments.

2.3 RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)

Trizol Reagent (Invitrogen, Carlsbad, CA, USA) was applied for the total RNA extraction from GC tissues and the cultured GC cell lines according to the manufacture’s protocol. RNA was reverse transcribed into cDNA using the miScript Reverse Transcription Kit (QIAGEN, Germany). qRT-PCR was performed using SYBR green I Master Mix kit (Invitrogen, Carlsbad, CA, USA) and 7300 Real-Time PCR System (Applied Biosystems, USA) to estimate the expression of miR-181d. Then the relative expressions of miR-181d were normalized to U6. The expression fold change was determined using the comparative delta CT (2 ${}^{-\Delta\Delta Ct}$ ) method.

2.4 MTT assay

Cellular proliferation of the stably transfected cells was calculated using an MTT assay. Transfected cells were collected at 48 h post-transfection and seeded into a 96-well plate with the density of 5 $\times$ 10 ${}^{4}$ cells per well. Following incubation for 0, 24, 48, 72 h at 37 ${}^{\circ}$ C with 5% CO ${}_{2}$ , 20 $\mu$ l of MTT (5 mg/ml; Sigma-Aldrich; Merck, Darmstadt, Germany) was added to each well respectively at each time point. The cells were then incubated at 37 ${}^{\circ}$ C with 5% CO ${}_{2}$ for 4 h, followed by addition of 150 $\mu$ l of dimethyl sulfoxide (DMSO) (Sigma-Aldrich; Merck). The absorbance of cells at 490 nm was estimated using a microplate reader. Each assay was repeated three times.

2.5 Transwell assay

Cell migration was measured using 6.5 mm Transwell inserts with 8 $\mu$ m pore size polycarbonate membranes (Corning, USA). Cell invasion assays were performed in the same way, but the membranes using for invasion analysis were pre-coated with Matrigel (Corning, USA). In brief, the stably transfected cells (5 $\times$ 10 ${}^{4}$ cells/well) were seeded into the upper chamber of the inserts in serum-free medium, while the 300 $\mu$ l DMEM containing 10% FBS was added to the lower chambers. After 24 h post incubation at 37 ${}^{\circ}$ C, cells on the upper surface of the membrane were removed, while cells in the lower membrane were stained with 0.1% crystal violet at a room temperature for 20 min. Then the stained cells were observed using a light microscopy (magnification, x100; Olympus Corporation, Tokyo, Japan) and counted in a random five fields of view from each well. The mean number of migrated or invaded cells was calculated.

2.6 Statistical analysis

All statistical analysis were performed using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 software (GraphPad Software, Inc., USA). Student’s $t$ test was used for two groups comparisons, while one-way ANOVA analysis were applied to analyze multiple groups for statistical significance. Association of miR-181d expression with clinicopathological features was estimated by chi-square test. Kaplan-Meier methods and log-rank test were performed to assess the survival rate of the GC patients. Cox regression analysis was conducted to further determine the prognostic value of miR-181d in GC. $P$ values less than 0.05 were considered statistically significant.

3. Results

3.1 Overexpression of miR-181d in GC tissues and cell lines

The expression of miR-181d was examined in a set of 131 paired samples using qRT-PCR. The results suggested that miR-181d was significantly up-regulated in GC tissues when compared to the adjacent normal tissues ( $P<$ 0.001, Fig. 1A). Furthermore, the miR-181d expression was also analyzed in three GC cell lines (NCI-N87, AGS, and MGC-803), higher expression levels were detected in all GC cell lines compared to normal GES-1 cells, and all differences reached significant level (all $P<$ 0.001, Fig. 1B).

Table 1
Association of miR-181d with the clinicopathological features of gastric cancer patients

Features	Total no.	miR-181d expression		$P$ values
	$N=$ 131	Low ( $n=$ 61)	High ( $n$ = 70)
Age (years)				0.523
$\leqslant$ 60	52	26	26
$>$ 60	79	35	44
Gender
Male	70	30	40	0.362
Female	61	31	30
Perineural invasion				0.898
Absence	83	39	44
Presence	48	22	26
Histological type				0.928
Differentiated	80	37	43
Undifferentiated	51	24	27
Tumor depth				0.367
T1–T2	91	40	51
T3–T4	40	21	19
TNM stage				0.003 ${}^{**}$
I–II	74	43	31
III–IV	57	18	39
Lymph node metastasis				0.042 ${}^{*}$
No	67	37	30
Yes	64	24	40

${}^{*}P<$ 0.05; ${}^{**}P<$ 0.01.

Figure 1.

Expression of miR-181d measured by qRT-PCR in GC tissues and cell lines. A. MiR-181d expression was upregulated in the GC tissues compared with the adjacent normal controls ( ${}^{***}P<$ 0.001). B. The expression of miR-181d was higher in the GC cell lines than that in the normal gastric cells ( ${}^{***}P<$ 0.001).

3.2 Association of miR-181d expression with clinicopathological features of GC patients

The correlation of miR-181d with the clinicopathological characteristics was further investigated. As shown in Table 1, all GC patients were divided into low ( $n=$ 61) and high miR-181d expression ( $n=$ 70) groups according to the mean expression value (9.869) as the cutoff value. It was found that miR-181d expression showed significant association with TNM stage ( $P=$ 0.003) and lymph node metastasis ( $P=$ 0.042), although it was not correlated with the age, gender, perineural invasion, histological type and tumor depth (all $P>$ 0.05, Table 1).

3.3 Prognostic value of miR-181d expression for patients with GC

The Kaplan-Meier survival curves was applied to calculate the prognostic value of miR-181d. The results revealed that the GC patients with high miR-181d expression had a shorter survival time, when compared with those presenting a low miR-181d expression (log-rank $P<$ 0.001, Fig. 2). Additionally, the multivariate Cox analysis was performed to further investigate the influence of the clinical parameters on overall survival of the cancer patients. As shown in Table 2, miR-181d expression (HR $=$ 3.128, 95% CI $=$ 1.558–6.281, $P=$ 0.001) and TNM stage (HR $=$ 1.959, 95% CI $=$ 1.056–3.634, $P=$ 0.033) were considered to be two independent prognostic factors for GC.

Table 2
Multivariate Cox regression analysis for miR-181d in gastric cancer patients

Variables	Multivariate analysis
	HR	95% CI	$P$ value
MiR181d	3.128	1.558–6.281	0.001 ${}^{**}$
Age	1.184	0.646–2.170	0.586
Gender	1.047	0.561–1.953	0.885
Perineural invasion	1.134	0.628–2.046	0.677
Histological type	1.117	0.626–1.993	0.709
Tumor depth	1.409	0.786–2.527	0.250
TNM stage	1.959	1.056–3.634	0.033 ${}^{*}$
Lymph node metastasis	1.341	0.732–2.456	0.342

${}^{*}P<$ 0.05; ${}^{**}P<$ 0.01.

Figure 2.

Kaplan-Meier survival analysis for the GC patients based on the expression of miR-181d. Patients with high miR-181d expression had shorter survival time than those with low miR-181d expression (log-rank $P<$ 0.001).

3.4 Effects of miR-181d on cell proliferation, migration and invasion in GC cells

Since miR-181d expression levels were upregulated to a greater extent in NCI-N87 and MGC-803 cells, the two cell lines were used in subsequent experiments. NCI-N87 and MGC-803 cells were then transfected with miR-181d mimic, inhibitor or the corresponding negative controls. As shown in Fig. 3A, in both NCI-N87 and MGC-803 cells, the miR-181d expression levels were significantly higher in the miR-181d mimic group compared with the mimic NC group, while were lower in the miR-181d inhibitor group (all $P<$ 0.01). MTT assay was performed to investigate the role of miR-181d on the proliferation of GC cells. We found that overexpression of miR-181d promoted NCI-N87 cell proliferation as compared with the negative control, while down-regulation of miR-181d expression had contrary results. The same result was also confirmed in MGC-803 cells (all $P<$ 0.05, Fig. 3B). To investigate the effect of miR-181d on GC cell migration and invasion abilities, the transwell assay was carried out. The data suggested that in both NCI-N87 and MGC-803 cells, the number of migrated and invasive cells in miR-181d mimic groups were increased significantly than those in mimic NC groups (all $P<$ 0.001, Fig. 3C and D). Inversely, both migrated and invasive cells counts were lower in miR-181d inhibitor groups than that in inhibitor NC groups, and all differences reached significant level ( $P<$ 0.001, Fig. 3C and D).

Figure 3.

Effects of miR-181d on cell proliferation, migration and invasion in NCI-N87 and MGC-803 cells. A. In the two cell lines, expression of miR-181d was significantly increased by miR-181d mimic transfection, but was decreased by miR-181d inhibitor transfection compared with the corresponding negative controls ( ${}^{**}P<$ 0.01 and ${}^{***}P<$ 0.001). B. Cell proliferation was enhanced by overexpression of miR-181d, but was suppressed by knockdown of miR-181d in both NCI-N87 and MGC-803 cells ( ${}^{*}P<$ 0.05 and ${}^{**}P<$ 0.01). C and D. Overexpression of miR-181d by miR-181d mimic transfection could promote the cell migration and invasion, but the downregulated miR-181d expression could inhibit the cell migration and invasion ( ${}^{***}P<$ 0.001).

4. Discussion

GC is regarded to be a major cause of cancer related mortality worldwide, as a result of the untimely diagnosis [15]. It is reported that 98% of patients with early GC are alive at five years after the clinical treatment, but patients with advanced GC may have relatively poor prognosis as a result of distant metastasis [16]. Tumor recurrence and metastasis are considered to be the main causes of poor prognosis for GC patients [17]. As previous studies reported, the proliferation and metastasis of GC cells can be affected by various genes and multiple factors [18, 19]. MiRNA has huge abilities of post transcriptional regulation, in addition to possessing broad application prospect in tumor therapy. Aberrant expression of miRNAs has been reported in many kinds of human cancers, and the dysregulation of miRNAs plays a crucial role in the progression of different cancers [20, 21, 22]. Assumpção et al. have identified a number of aberrantly expressed miRNAs in GC through a high-throughput sequencing of miRnome of four GC samples, such as miR-3131, miR-664, miR-150 and so on [11]. Previous evidences have demonstrated that miR-181d was upregulated in GC [23, 24], but its clinical and function role have not been studied.

MiR-181d is a member of miR-181 family, which contains miR-181a, miR-181b, miR181c and miR-181d. MiR-181d has been reported to be abnormally expressed in many kinds of human cancers. For example, Li et al. found that miR-181d was downregulated in both Esophageal squamous cell carcinoma (ESCC) cell lines and clinical samples, and DERL1 might be the target gene of miR-181d in ESCC [25]. Huang et al. demonstrated that miR-181d expression level was lower in colorectal cancer (CRC) tissues, and the down-regulation of miR-181d was significantly associated with poor prognosis for CRC patients [26]. Wang et al. revealed that low expression of miR-181d was detected in both glioma tissues and cell lines, indicating miR-181d to be a glioma suppressor [27]. In contrast, up-regulation of miR-181d was detected in human pancreatic carcinoma and cell lines, which can promote the cancer cell proliferation, migration and fluorouracil resistance, and NKAIN2 was considered as the direct target [28]. In the present study, the expression level of miR-181d was proved to be up-regulated in both GC tissues and cell lines. As reported in the previous evidences, miR-181d was up-regulated in GC [29]. Besides, Ueda et al. performed miRNA microarray in 353 gastric samples and proved that miR-181d was up-regulated in GC, which was also reported by An et al. [24, 29]. All evidences supported our present results. Additionally, our study documented that the expression level of miR-181d showed significant association with TNM stage and lymph node metastasis. The effect that miR-181d had on GC behaviors was further investigated, and cellular functional experiments indicated that up-regulated miR-181d expression promoted cell proliferation, migration and invasion in GC. We concluded that miR-181d might be an oncogene in GC, and play a vital role in the cancer progression.

We further investigated the clinical value of miR-181d in GC prognosis, and Kaplan-Meier survival analysis suggested that GC patients in the higher miR-181d expression group had shorter survival time than those in the low miR-181d expression group. Multivariate Cox regression analysis demonstrated that miR-181d expression and TNM stage were two independent prognostic marker for GC. Accordingly, miR-181d might be a novel predictive marker for the poor prognosis of GC patients and involved in the development of GC.

About the oncogenic function of miR-181d, several studies have been reported in different kind of cancer, which supported the present results. Consistently, Zhang et al. found that miR-181d had higher expression level in human pancreatic carcinoma, and down-regulated miR-181d can inhibit pancreatic cancer proliferation, migration in vitro and suppress the growth of cancer explant in vivo [28]. Strotbek et al. reported the oncogenic function of miR-181family in luminal breast cancer including miR-181d, and PH domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) was proved to be the target gene of miR-181d, which may be involved in PI3K-Akt pathway [30]. PHLPP2 is an isoform of the PHLPP, which has been proved to induce cell apoptosis and inhibit tumor metastasis of several kind of human cancers [31, 32]. Notably, Ding et al. recently reported that PHLPP2 mRNA expression was lower in GC tissues compared to adjacent normal tissues, and high malignant-degree tumor tissues have lower PHLPP2 expression [33]. Furthermore, previous researches have suggested that PHLPP2 can regulate the phosphatase activity of Akt, and further be involved in regulating Akt signaling pathway [34, 35]. Interestingly, Akt signaling pathway has been widely reported to show closely correlation with GC progression [36, 37]. The present results revealed that miR-181d expression was up-regulated in GC, we inferred that miR-181d may promote tumor progression in GC via targeting PHLPP2 and activating Akt signaling pathway. But further studies are needed to verify our hypothesis.

In summary, the present study suggested that miR-181d had a high expression level in both GC tissues and cell lines. MiR-181d may serve a role as an oncogene in GC by promoting cell proliferation, migration and invasion. And miR-181d might be a novel predictive marker for the prognosis of GC patients, miR-181d may act as a potential novel therapeutic target in GC. Further researches involved in target genes are still in demand to further explore the mechanism of miR-181d in GC.

Footnotes

Conflict of interest

The authors have declared no conflict of interest.

References

Irmak-Yazicioglu

M.B.

, Mechanisms of MicroRNA Deregulation and MicroRNA Targets in Gastric Cancer, Oncol Res Treat 39 (2016), 136–139.

Guggenheim

D.E.

and Shah

M.A.

, Gastric cancer epidemiology and risk factors, J Surg Oncol 107 (2013), 230–236.

Osumi

Takahari

Chin

Ogura

Ichimura

Wakatsuki

Suzuki

Ota

Nakayama

Ooki

Suenaga

Shinozaki

and Yamaguchi

, Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake, Onco Targets Ther 11 (2018), 8301–8307.

Fang

Gao

Shi

Liu

and Yuan

, Barrier-to-autointegration factor 1: A novel biomarker for gastric cancer, Oncol Lett 16 (2018), 6488–6494.

Sun

Wang

and Gu

, Recent advances of cocktail chemotherapy by combination drug delivery systems, Adv Drug Deliv Rev 98 (2016), 19–34.

Zhang

, Apatinib for molecular targeted therapy in tumor, Drug Des Devel Ther 9 (2015), 6075–6081.

Tusong

Maolakuerban

Guan

Rexiati

Wang

W.G.

Azhati

Nuerrula

and Wang

Y.J.

, Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma, Cancer Biomark 18 (2017), 79–85.

Zhang

Q.A.

H.Y.

Chen

Yan

Jing

F.C.

Liu

H.Q.

and Zhang

, miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA, Cancer Biomark (2018).

Liu

Luo

Pan

Yang

Gao

Chen

and He

, MicroRNA-195 as a diagnostic biomarker in human cancer detection: A meta-analysis, Oncol Lett 16 (2018), 6253–6260.

10.

Fabian

M.R.

Sonenberg

and Filipowicz

, Regulation of mRNA translation and stability by microRNAs, Annu Rev Biochem 79 (2010), 351–379.

11.

Assumpcao

M.B.

Moreira

F.C.

Hamoy

I.G.

Magalhaes

Vidal

Pereira

Burbano

Khayat

Silva

Santos

Demachki

Ribeiro-Dos-Santos

and Assumpcao

, High-Throughput miRNA Sequencing Reveals a Field Effect in Gastric Cancer and Suggests an Epigenetic Network Mechanism, Bioinform Biol Insights 9 (2015), 111–117.

12.

Tian

Wang

Z.Y.

Hao

and Zhang

X.Y.

, miR-505 acts as a tumor suppressor in gastric cancer progression through targeting HMGB1, J Cell Biochem (2018).

13.

Guo

Zhao

Yang

Huang

and Zhang

, MicroRNA-371a-3p promotes progression of gastric cancer by targeting TOB1, Cancer Lett 443 (2019), 179–188.

14.

Wang

Steele

Kumar

J.D.

Dimaline

Jithesh

P.V.

Tiszlavicz

Reisz

Dockray

G.J.

and Varro

, Distinct miRNA profiles in normal and gastric cancer myofibroblasts and significance in Wnt signaling, Am J Physiol Gastrointest Liver Physiol 310 (2016), G696–704.

15.

Ferlay

Soerjomataram

Dikshit

Eser

Mathers

Rebelo

Parkin

D.M.

Forman

and Bray

, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer 136 (2015), E359–386.

16.

Singh

Toom

and Huang

, Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer, J Hematol Oncol 10 (2017), 105.

17.

Lin

X.L.

Tang

Sun

Han

Wang

L.W.

and Xiao

X.Y.

, Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway, PLoS One 12 (2017), e0177335.

18.

Zeng

X.Q.

Wang

and Chen

S.Y.

, Methylation modification in gastric cancer and approaches to targeted epigenetic therapy (Review), Int J Oncol 50 (2017), 1921–1933.

19.

Hayakawa

Fox

J.G.

and Wang

T.C.

, The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models, Cell Mol Gastroenterol Hepatol 3 (2017), 331–338.

20.

Khawar

M.B.

Mehmood

and Roohi

, MicroRNAs: Recent insights towards their role in male infertility and reproductive cancers, Bosn J Basic Med Sci (2019).

21.

Noori

Sharifi

and Haghjooy Javanmard

, miR-30a Inhibits Melanoma Tumor Metastasis by Targeting the E-cadherin and Zinc Finger E-box Binding Homeobox 2, Adv Biomed Res 7 (2018), 143.

22.

Zhao

Chen

Liu

and Yin

, Overexpression of miRNA-143 Inhibits Colon Cancer Cell Proliferation by Inhibiting Glucose Uptake, Arch Med Res (2018).

23.

Dumortier

Hinault

and Van Obberghen

, MicroRNAs and metabolism crosstalk in energy homeostasis, Cell Metab 18 (2013), 312–324.

24.

Ueda

Volinia

Okumura

Shimizu

Taccioli

Rossi

Alder

Liu

C.G.

Oue

Yasui

Yoshida

Sasaki

Nomura

Seto

Kaminishi

Calin

G.A.

and Croce

C.M.

, Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis, Lancet Oncol 11 (2010), 136–146.

25.

Shi

Chen

Jiang

and Wang

, MicroRNA-181d is a tumor suppressor in human esophageal squamous cell carcinoma inversely regulating Derlin-1, Oncol Rep 36 (2016), 2041–2048.

26.

Huang

Wen

Yang

Lou

Wang

Che

Chen

Yang

Huang

Lan

Wang

Iwamoto

Wang

and Liu

, PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d, Cell Death Dis 9 (2018), 271.

27.

Wang

X.F.

Shi

Z.M.

Wang

X.R.

Cao

Wang

Y.Y.

Zhang

J.X.

Yin

Luo

Kang

C.S.

Liu

Jiang

and You

Y.P.

, MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2, J Cancer Res Clin Oncol 138 (2012), 573–584.

28.

Zhang

Liu

Long

Shi

Qiu

and Liu

, Downregulation of microRNA-181d had suppressive effect on pancreatic cancer development through inverse regulation of KNAIN2, Tumour Biol 39 (2017), 1010428317698364.

29.

Pan

Yan

Cui

Yuan

Tian

Xing

and Lu

, MiR-23a in amplified 19p13.13 loci targets metallothionein 2A and promotes growth in gastric cancer cells, J Cell Biochem 114 (2013), 2160–2169.

30.

Strotbek

Schmid

Sanchez-Gonzalez

Boerries

Busch

and Olayioye

M.A.

, miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer, Int J Cancer 140 (2017), 2310–2320.

31.

Liao

Deng

Liu

You

Yao

and He

, MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression, Gynecol Oncol 143 (2016), 655–663.

32.

C.F.

Y.C.

Jin

J.P.

Yan

Z.K.

and Li

D.D.

, miR-938 promotes colorectal cancer cell proliferation via targeting tumor suppressor PHLPP2, Eur J Pharmacol 807 (2017), 168–173.

33.

Ding

Zhang

Sui

and Yang

, MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2, J Exp Clin Cancer Res 36 (2017), 45.

34.

Brognard

Niederst

Reyes

Warfel

and Newton

A.C.

, Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C, J Biol Chem 284 (2009), 15215–15223.

35.

Brognard

Sierecki

Gao

and Newton

A.C.

, PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms, Mol Cell 25 (2007), 917–931.

36.

Wang

Ouyang

Liu

H.M.

Wang

Zhu

and Zhang

, Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway, Oncotarget 7 (2016), 3791–3805.

37.

Wang

Z.Q.

Cai

C.Y.

J.F.

Quan

Z.W.

Liu

B.Y.

and Zhu

Z.G.

, Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer, Cell Death Dis 8 (2017), e2839.

Increased expression of miR-181d is associated with poor prognosis and tumor progression of gastric cancer

Abstract

Keywords

1. Introduction

2. Materials and methods

2.1 Patients and sample collection

2.2 Cell culture and transfection

2.3 RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)

2.4 MTT assay

2.5 Transwell assay

2.6 Statistical analysis

3. Results

3.1 Overexpression of miR-181d in GC tissues and cell lines

Table 1 Association of miR-181d with the clinicopathological features of gastric cancer patients

3.3 Prognostic value of miR-181d expression for patients with GC

Table 2 Multivariate Cox regression analysis for miR-181d in gastric cancer patients

Footnotes

Conflict of interest

References

Table 1
Association of miR-181d with the clinicopathological features of gastric cancer patients

Table 2
Multivariate Cox regression analysis for miR-181d in gastric cancer patients